177 completed, 14 terminated, 8 recruiting, 3 unknown. 206 Phase 1, 4 Phase 2.
By phase and status
Follow Renal Impairment: new trials by email Literature Review of Renal Impairment trials Research Report on Renal Impairment
Trials (filtered) newest first · largest first
All 206 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls Sulthiame - Renal Impairment Phase 1 Not yet recruiting 30 2026-09-29 2026-10-05 Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function rilzabrutinib - Renal Impairment, Healthy Volunteers Phase 1 Recruiting 16 2026-09-22 2026-10-23 Renal Impairment Pharmacokinetics (PK) Trial of Afabicin Afabicin Oral, Afabicin IV - Renal Impairment Phase 1 Recruiting 60 2026-09-16 2026-10-26 A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions RO7795081 - Renal Impairment Phase 1 Recruiting 60 2026-09-09 2026-10-09 A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide Ribupatide - End Stage Renal Disease, Renal Impairment Phase 1 Recruiting 32 2026-09-08 2026-10-01 The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function. D-2570 - Renal Impairment Phase 1 Recruiting 40 2026-08-08 2026-10-13 A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease INCB123667 - Renal Impairment Phase 1 Recruiting 16 2026-05-29 2026-06-16 Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function VC005 Tablets - Renal Impairment Phase 1 Completed 32 2026-05-09 2026-08-20 A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) MK-2828 - Chronic Kidney Failure, End-Stage Renal Disease Phase 1 Completed 18 2026-03-02 2026-09-15 A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function LY3841136 - Kidney Disease, Renal Insufficiency Chronic Phase 1 Active not recruiting 28 2026-02-24 2026-08-19 A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function PF-07328948 - Renal Impairment, Healthy Phase 1 Recruiting 28 2026-01-28 2026-05-12 A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls S-892216-PO - Renal Impairment Phase 1 Completed 24 2025-10-16 2026-10-22 A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment LY3537031 - Renal Impairment, Healthy Phase 1 Completed 31 2025-09-18 2026-04-24 Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls BPN14770 - Renal Impairment Phase 1 Completed 14 2025-08-25 2026-02-27 Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373) Opemalirsen (AZD2373) - Renal Impairment Phase 1 Completed 35 2025-08-18 2026-06-26 An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function ESK-001 - Renal Impairment Phase 1 Completed 16 2025-04-23 2025-12-10 Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function Petrelintide - Renal Impairment Phase 1 Completed 39 2025-04-15 2026-01-28 Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination - Healthy Volunteer Study, Hepatic Impairment Phase 1 Completed 28 2025-04-09 2026-07-31 A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010) Calderasib - Healthy, Renal Impairment Phase 1 Completed 34 2025-04-07 2026-02-13 Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants TNO155 - Renal Impairment Phase 1 Withdrawn 2025-03-19 2024-02-29
Showing 20 of 206. Sign in to see all of them.
Narrower conditions Renal Insufficiency (206) · Kidney Failure, Chronic (14) · Kidney Diseases (11) · Diabetes Mellitus, Type 2 (5) · Lymphoma, Follicular (5) · Renal Insufficiency, Chronic (5) · Heart Failure (3) · Cardiomyopathies (2) · Diabetes Mellitus (2) · Anemia (1) · Anemia, Sickle Cell (1) · Arthritis, Rheumatoid (1) · COVID-19 (1) · Hepatitis C, Chronic (1) · Hypertension (1)
Broader conditions Female Urogenital Diseases (206) · Female Urogenital Diseases and Pregnancy Complications (206) · Male Urogenital Diseases (206) · Urogenital Diseases (206) · Urologic Diseases (206) · Kidney Diseases (195) · Chronic Disease (17) · Disease Attributes (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Renal Insufficiency, Chronic (11) · Cardiovascular Diseases (8) · Hemic and Lymphatic Diseases (8) · Immune System Diseases (7) · Nutritional and Metabolic Diseases (7)
Interventions (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (2) · AT-511 (2) · Cefepime (2) · Tablets (2) · Tadalafil (2) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (1) · 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1) · 4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one (1) · ALKS 5461 (1) · ALN-PCS (1) · AZD4831 (1) · AZD9977 (1) · BI 456906 (1) · BPN14770 (1) · Cholestyramine Resin (1)
Sponsors AstraZeneca (16) · Pfizer (14) · Merck Sharp & Dohme LLC (13) · Novartis Pharmaceuticals (11) · Shionogi (5) · Bayer (4) · Bristol-Myers Squibb (4) · Sanofi (4) · AbbVie (3) · Amgen (3) · Astellas Pharma Global Development, Inc. (3) · Eisai Inc. (3) · Haisco Pharmaceutical Group Co., Ltd. (3) · Janssen Research & Development, LLC (3) · Takeda (3)
Countries United States (124) · Germany (30) · China (13) · Bulgaria (8) · Hungary (6) · Japan (5) · New Zealand (5) · Romania (5) · Canada (4) · Czechia (4) · South Korea (4) · Portugal (3) · Belgium (2) · France (2) · Moldova (2)
Top investigators Thomas Marbury, MD (3) · Horng H Chen, MD (2)
Results publications PMID 21960668 , PMID 23737404 , PMID 24030917 , PMID 24408516 , PMID 24760402 , PMID 24946021 , PMID 25136024 , PMID 25529979 , PMID 26519231 , PMID 28349386 , PMID 28365033 , PMID 28679468 , PMID 28703316 , PMID 29263061 , PMID 29891610 , PMID 30012756 , PMID 30194585 , PMID 30397067 , PMID 30680407 , PMID 31332068 , PMID 31630870 , PMID 31632000 , PMID 32579796 , PMID 32868037 , PMID 33388951 , PMID 33813736 , PMID 34115385 , PMID 34213819 , PMID 34637151 , PMID 35001638 , PMID 35018553 , PMID 35420493 , PMID 35712797 , PMID 36811175 , PMID 36977960 , PMID 37070852 , PMID 37295665 , PMID 37801266 , PMID 37840155 , PMID 37917289 , PMID 38184489 , PMID 38746989 , PMID 38770818 , PMID 39574348 , PMID 39601078 , PMID 42032338 , PMID 42059789
NIH funding 2017 (4) , 2018 (4) , 2019 (3) , 2008 (1) , 2014 (1) , 2023 (1)